Ironwood Pharmaceuticals Inc. (IRWD)

17.55
0.07 0.37
NASDAQ : Health Technology
Prev Close 17.49
Open 17.58
Day Low/High 17.48 / 17.71
52 Wk Low/High 12.89 / 19.94
Volume 137.68K
Avg Volume 1.48M
Exchange NASDAQ
Shares Outstanding 137.61M
Market Cap 2.62B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2017 Investor Update Call

Ironwood Pharmaceuticals To Host Fourth Quarter And Full-Year 2017 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2017 investor update conference call and webcast at 8:30 a.

Ironwood And Allergan Announce Settlement With Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood And Allergan Announce Settlement With Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with wholly-owned subsidiaries of Sun Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 36 th Annual J.

First Week Of August 2018 Options Trading For Ironwood Pharmaceuticals (IRWD)

First Week Of August 2018 Options Trading For Ironwood Pharmaceuticals (IRWD)

Investors in Ironwood Pharmaceuticals Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ironwood Pharmaceuticals Initiates Phase II Clinical Trial Of SGC Stimulator IW-1701 In Patients With Sickle Cell Disease

Ironwood Pharmaceuticals Initiates Phase II Clinical Trial Of SGC Stimulator IW-1701 In Patients With Sickle Cell Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the initiation of STRONG-SCD, a Phase II clinical trial evaluating once-daily IW-1701, an orally administered soluble...

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers

The Cambridge, Mass.-based Ironwood unveiled top-line data from a pair of Phase 2a studies evaluating IW-1973 in patients that have type 2 diabetes and hypertension.

Ironwood Reports Top-line Phase IIa Data For IW-1973 Demonstrating Positive Cardiovascular, Metabolic And Endothelial Effects

Ironwood Reports Top-line Phase IIa Data For IW-1973 Demonstrating Positive Cardiovascular, Metabolic And Endothelial Effects

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced encouraging top-line results from two Phase IIa studies of IW-1973, Ironwood's lead investigational soluble guanylate cyclase (sGC) stimulator, in patients...

Ironwood Pharmaceuticals Strengthens Executive Leadership Team

Ironwood Pharmaceuticals Strengthens Executive Leadership Team

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of William Huyett as chief operating officer and the promotion of Gina Consylman to senior vice...

Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update

Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today provided an update on its third quarter 2017 results and recent business activities.

Ironwood Pharmaceuticals To Present At Credit Suisse 26th Annual Healthcare Conference

Ironwood Pharmaceuticals To Present At Credit Suisse 26th Annual Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Credit Suisse 26 th Annual Healthcare Conference on Wednesday, November 8 th, 2017 at 10:25 a.

Ironwood Highlights Breadth Of Gout Research To Be Presented At The 2017 ACR/ARHP Annual Meeting

Ironwood Highlights Breadth Of Gout Research To Be Presented At The 2017 ACR/ARHP Annual Meeting

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017.

Ironwood Pharmaceuticals To Host Third Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals To Host Third Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2017 investor update conference call and webcast at 8:30 a.

Ironwood Pharmaceuticals Presenting Linaclotide Data At The World Congress Of Gastroenterology At ACG 2017

Ironwood Pharmaceuticals Presenting Linaclotide Data At The World Congress Of Gastroenterology At ACG 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today announced that the company and its collaborators are presenting clinical data for linaclotide at the World Congress of...

Ironwood Pharmaceuticals Announces Leadership Change

Ironwood Pharmaceuticals Announces Leadership Change

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that Tom Graney, chief financial officer (CFO) and senior vice president, finance and corporate strategy will leave the company, effective September 13, 2017,...

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals To Present At Upcoming September Investor Conferences

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017...

Ironwood Pharmaceuticals Stock Sees Short Interest Move 16% Higher

Ironwood Pharmaceuticals Stock Sees Short Interest Move 16% Higher

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 2,249,386 share increase in total short interest for Ironwood Pharmaceuticals Inc , to 16,348,161, an increase of 15.95% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

The Cambridge, Mass.-based firm clinched FDA approval for hyperuricemia drug Duzallo.

DUZALLO(R) (lesinurad And Allopurinol) (Photo: Business Wire)

DUZALLO(R) (lesinurad And Allopurinol) (Photo: Business Wire)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced DUZALLO was approved by the U.

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today provided an update on its second quarter 2017 results and recent business activities.

Ironwood Pharmaceuticals To Host Second Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals To Host Second Quarter 2017 Investor Update Call

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its second quarter 2017 investor update conference call and webcast at 4:30 p.

Ironwood Pharmaceuticals Reports Positive Top-line Results From IW-3718 Phase IIb Trial In Uncontrolled Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals Reports Positive Top-line Results From IW-3718 Phase IIb Trial In Uncontrolled Gastroesophageal Reflux Disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, announced positive top-line data from a Phase IIb clinical trial evaluating IW-3718 in adult patients with uncontrolled...

Ironwood Pharmaceuticals To Present At The Goldman Sachs 38th Annual Global Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Goldman Sachs 38 th Annual Global Healthcare Conference on Thursday, June 15, 2017 at 10:00 a.

Ironwood Pharmaceuticals To Present At The Jefferies Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Jefferies Healthcare Conference on Thursday, June 8, 2017 at 4:00 p.

Ironwood Pharmaceuticals To Present At The Bank Of America Merrill Lynch Healthcare Conference

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 17, 2017 at 1:00 p.

Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect On Pain At Digestive Disease Week® 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, this week presented clinical data on the effect of linaclotide on abdominal pain in irritable bowel syndrome with constipation (IBS-C)...

Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today provided an update on its first quarter 2017 results and recent business activities.

Ironwood Pharmaceuticals To Present New Data For Linaclotide, Linaclotide Delayed Release And IW-1701 At Digestive Disease Week® 2017

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced that the company and its collaborators will present clinical and preclinical data for linaclotide and linaclotide...

First Week of IRWD June 16th Options Trading

Investors in Ironwood Pharmaceuticals Inc. saw new options become available this week, for the June 16th expiration.

TheStreet Quant Rating: D (Sell)